WebJun 7, 2024 · Introducing PARAGON-II, a new trial for women with rare gynaecological cancers. 07 Jun 2024 ANZGOG’s rare tumour, basket study, PARAGON-II, has officially … WebApr 10, 2024 · Ces données rétrospectives ont été confirmées dans le premier essai prospectif de phase 2, l’étude PARAGON-ANZGOG0309. ... the PARAGON/ANZGOG 0903 trial. Gynecol Oncol, 163 (2024), pp. 72-78, 10.1016/j.ygyno.2024.07.024. View PDF View article View in Scopus Google Scholar [43]
A phase 2 study of anastrozole in patients with oestrogen …
WebSep 1, 2024 · PARAGON (ANZGOG-0903): A phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression Project:... WebThe Paragon study is a basket protocol that includes a series of phase 2 trials investigating the activity of anastrozole in patients with estrogen or progesterone receptor–positive recurrent gynecological cancers. We report the results of treatment in patients with platinum-resistant or -refractory recurrent epithelial ovarian cancer. daugherty\\u0027s decatur il
Introducing PARAGON-II, a new trial for women with rare …
WebAug 16, 2024 · PARAGON is an investigator-initiated single-arm open-label multicentre phase 2 trial, designed to evaluate the activity of anastrozole in post-menopausal … WebMay 20, 2024 · The phase 2 PARAGON trial, which investigated anastrozole in a variety of gynecologic cancers, included a cohort of 41 postmenopausal recurrent granulosa cell tumor patients with estrogen... WebThe Paragon study is a basket protocol that includes a series of phase 2 trials investigating the activity of anastrozole in patients with estrogen or progesterone receptor–positive recurrent gynecological cancers. ... Median progression-free survival was 2.7 months (95% CI, 2.0–2.8 months). The median duration of clinical benefit was 2.8 ... daugherty\u0027s drugs pine knot